Clinical and radiation treatment characteristics
| . | All . | No CH . | Non-DDR CH . | DDR CH . |
|---|---|---|---|---|
| N = 2195 . | n = 1691 . | n = 346 . | n = 158 . | |
| Sex | ||||
| Female | 1167 (53.2%) | 926 (79.3%) | 169 (14.5%) | 72 (6.17%) |
| Male | 1028 (46.8%) | 765 (74.4%) | 177 (17.2%) | 86 (8.37%) |
| Age, y | 60.7 (51.2-69.1) | 58.2 (48.4-66.7) | 68.4 (60.0-73.4) | 69.0 (62.3-74.7) |
| Primary tumor subtype | ||||
| Breast carcinoma | 395 (18.0%) | 325 (82.3%) | 52 (13.2%) | 18 (4.56%) |
| Cancer of unknown primary | 66 (3.01%) | 44 (66.7%) | 12 (18.2%) | 10 (15.2%) |
| Colorectal cancer | 155 (7.06%) | 126 (81.3%) | 21 (13.5%) | 8 (5.16%) |
| Endometrial cancer | 72 (3.28%) | 47 (65.3%) | 12 (16.7%) | 13 (18.1%) |
| Esophagogastric carcinoma | 93 (4.24%) | 68 (73.1%) | 14 (15.1%) | 11 (11.8%) |
| Glioma | 162 (7.38%) | 141 (87.0%) | 17 (10.5%) | 4 (2.47%) |
| Head and neck carcinoma | 138 (6.29%) | 108 (78.3%) | 20 (14.5%) | 10 (7.25%) |
| Non–small cell lung cancer | 325 (14.8%) | 234 (72.0%) | 65 (20.0%) | 26 (8.00%) |
| Other | 399 (18.2%) | 310 (77.7%) | 65 (16.3%) | 24 (6.02%) |
| Pancreatic cancer | 83 (3.78%) | 61 (73.5%) | 13 (15.7%) | 9 (10.8%) |
| Prostate cancer | 160 (7.29%) | 113 (70.6%) | 34 (21.2%) | 13 (8.12%) |
| Soft tissue sarcoma | 97 (4.42%) | 81 (83.5%) | 12 (12.4%) | 4 (4.12%) |
| Thyroid cancer | 50 (2.28%) | 33 (66.0%) | 9 (18.0%) | 8 (16.0%) |
| Days between RT and blood draw | 267 (36.0-834) | 254 (29.5-808) | 355 (59.0-101) | 212 (60.0-565) |
| Modality | ||||
| IMRT | 787 (35.9%) | 608 (77.3%) | 121 (15.4%) | 58 (7.37%) |
| 3D | 308 (14.0%) | 238 (77.3%) | 41 (13.3%) | 29 (9.42%) |
| Conventional | 46 (2.10%) | 37 (80.4%) | 6 (13.0%) | 3 (6.52%) |
| VMAT | 263 (12.0%) | 200 (76.0%) | 42 (16.0%) | 21 (7.98%) |
| Multiple | 560 (25.5%) | 438 (78.2%) | 85 (15.2%) | 37 (6.61%) |
| Unknown | 231 (10.5%) | 170 (73.6%) | 51 (22.1%) | 10 (4.33%) |
| Anatomic site | ||||
| Abdomen | 124 (5.65%) | 95 (76.6%) | 17 (13.7%) | 12 (9.68%) |
| Arm/leg | 49 (2.23%) | 40 (81.6%) | 6 (12.2%) | 3 (6.12%) |
| Brain | 226 (10.3%) | 189 (83.6%) | 25 (11.1%) | 12 (5.31%) |
| Chest wall/breast | 282 (12.8%) | 220 (78.0%) | 48 (17.0%) | 14 (4.96%) |
| Head/neck | 262 (11.9%) | 199 (76.0%) | 44 (16.8%) | 19 (7.25%) |
| Multiple | 429 (19.5%) | 323 (75.3%) | 66 (15.4%) | 40 (9.32%) |
| Pelvis | 303 (13.8%) | 230 (75.9%) | 50 (16.5%) | 23 (7.59%) |
| Prostate | 77 (3.51%) | 58 (75.3%) | 16 (20.8%) | 3 (3.90%) |
| Rib/scapula/sternum | 7 (0.32%) | 5 (71.4%) | 1 (14.3%) | 1 (14.3%) |
| Spine | 118 (5.38%) | 102 (86.4%) | 13 (11.0%) | 3 (2.54%) |
| Thorax | 174 (7.93%) | 118 (67.8%) | 31 (17.8%) | 25 (14.4%) |
| Unknown | 144 (6.56%) | 112 (77.8%) | 29 (20.1%) | 3 (2.08%) |
| Chemotherapy modality | ||||
| Alkylating agent | 600 (27.33%) | 490 (81.66%) | 77 (12.83%) | 33 (5.50%) |
| Antimetabolite | 769 (35.03%) | 571 (74.25%) | 131 (17.03%) | 67 (8.71%) |
| Carboplatin | 461 (21.00%) | 321 (69.63%) | 70 (15.18%) | 70 (15.18%) |
| Cisplatin | 447 (20.36%) | 338 (75.61%) | 66 (14.76%) | 43 (9.61%) |
| Immune therapy | 175 (7.97%) | 131 (74.85%) | 29 (16.57%) | 15 (8.57%) |
| Microtubule damaging | 133 (6.05%) | 114 (85.71%) | 15 (11.27%) | 4 (3.00%) |
| No chemotherapy | 436 (19.86%) | 344 (78.90%) | 82 (18.81%) | 10 (2.29%) |
| Other cytotoxic therapy | 24 (1.09%) | 22 (91.66%) | 2 (8.33%) | 0 (0.00%) |
| Oxaliplatin | 273 (12.43%) | 208 (76.19%) | 43 (15.75%) | 22 (8.05%) |
| Radiopharmaceutical | 39 (1.77%) | 24 (61.53%) | 8 (20.51%) | 7 (17.94%) |
| Targeted therapy | 558 (25.42%) | 443 (79.39%) | 77 (13.79%) | 38 (6.81%) |
| Taxane | 764 (34.80%) | 575 (75.26%) | 111 (14.52%) | 78 (10.20%) |
| Topoisomerase I inhibitor | 186 (8.47%) | 140 (75.26%) | 23 (12.36%) | 23 (12.36%) |
| Topoisomerase II inhibitor | 542 (24.69%) | 418 (77.12%) | 80 (14.76%) | 44 (08.11%) |
| . | All . | No CH . | Non-DDR CH . | DDR CH . |
|---|---|---|---|---|
| N = 2195 . | n = 1691 . | n = 346 . | n = 158 . | |
| Sex | ||||
| Female | 1167 (53.2%) | 926 (79.3%) | 169 (14.5%) | 72 (6.17%) |
| Male | 1028 (46.8%) | 765 (74.4%) | 177 (17.2%) | 86 (8.37%) |
| Age, y | 60.7 (51.2-69.1) | 58.2 (48.4-66.7) | 68.4 (60.0-73.4) | 69.0 (62.3-74.7) |
| Primary tumor subtype | ||||
| Breast carcinoma | 395 (18.0%) | 325 (82.3%) | 52 (13.2%) | 18 (4.56%) |
| Cancer of unknown primary | 66 (3.01%) | 44 (66.7%) | 12 (18.2%) | 10 (15.2%) |
| Colorectal cancer | 155 (7.06%) | 126 (81.3%) | 21 (13.5%) | 8 (5.16%) |
| Endometrial cancer | 72 (3.28%) | 47 (65.3%) | 12 (16.7%) | 13 (18.1%) |
| Esophagogastric carcinoma | 93 (4.24%) | 68 (73.1%) | 14 (15.1%) | 11 (11.8%) |
| Glioma | 162 (7.38%) | 141 (87.0%) | 17 (10.5%) | 4 (2.47%) |
| Head and neck carcinoma | 138 (6.29%) | 108 (78.3%) | 20 (14.5%) | 10 (7.25%) |
| Non–small cell lung cancer | 325 (14.8%) | 234 (72.0%) | 65 (20.0%) | 26 (8.00%) |
| Other | 399 (18.2%) | 310 (77.7%) | 65 (16.3%) | 24 (6.02%) |
| Pancreatic cancer | 83 (3.78%) | 61 (73.5%) | 13 (15.7%) | 9 (10.8%) |
| Prostate cancer | 160 (7.29%) | 113 (70.6%) | 34 (21.2%) | 13 (8.12%) |
| Soft tissue sarcoma | 97 (4.42%) | 81 (83.5%) | 12 (12.4%) | 4 (4.12%) |
| Thyroid cancer | 50 (2.28%) | 33 (66.0%) | 9 (18.0%) | 8 (16.0%) |
| Days between RT and blood draw | 267 (36.0-834) | 254 (29.5-808) | 355 (59.0-101) | 212 (60.0-565) |
| Modality | ||||
| IMRT | 787 (35.9%) | 608 (77.3%) | 121 (15.4%) | 58 (7.37%) |
| 3D | 308 (14.0%) | 238 (77.3%) | 41 (13.3%) | 29 (9.42%) |
| Conventional | 46 (2.10%) | 37 (80.4%) | 6 (13.0%) | 3 (6.52%) |
| VMAT | 263 (12.0%) | 200 (76.0%) | 42 (16.0%) | 21 (7.98%) |
| Multiple | 560 (25.5%) | 438 (78.2%) | 85 (15.2%) | 37 (6.61%) |
| Unknown | 231 (10.5%) | 170 (73.6%) | 51 (22.1%) | 10 (4.33%) |
| Anatomic site | ||||
| Abdomen | 124 (5.65%) | 95 (76.6%) | 17 (13.7%) | 12 (9.68%) |
| Arm/leg | 49 (2.23%) | 40 (81.6%) | 6 (12.2%) | 3 (6.12%) |
| Brain | 226 (10.3%) | 189 (83.6%) | 25 (11.1%) | 12 (5.31%) |
| Chest wall/breast | 282 (12.8%) | 220 (78.0%) | 48 (17.0%) | 14 (4.96%) |
| Head/neck | 262 (11.9%) | 199 (76.0%) | 44 (16.8%) | 19 (7.25%) |
| Multiple | 429 (19.5%) | 323 (75.3%) | 66 (15.4%) | 40 (9.32%) |
| Pelvis | 303 (13.8%) | 230 (75.9%) | 50 (16.5%) | 23 (7.59%) |
| Prostate | 77 (3.51%) | 58 (75.3%) | 16 (20.8%) | 3 (3.90%) |
| Rib/scapula/sternum | 7 (0.32%) | 5 (71.4%) | 1 (14.3%) | 1 (14.3%) |
| Spine | 118 (5.38%) | 102 (86.4%) | 13 (11.0%) | 3 (2.54%) |
| Thorax | 174 (7.93%) | 118 (67.8%) | 31 (17.8%) | 25 (14.4%) |
| Unknown | 144 (6.56%) | 112 (77.8%) | 29 (20.1%) | 3 (2.08%) |
| Chemotherapy modality | ||||
| Alkylating agent | 600 (27.33%) | 490 (81.66%) | 77 (12.83%) | 33 (5.50%) |
| Antimetabolite | 769 (35.03%) | 571 (74.25%) | 131 (17.03%) | 67 (8.71%) |
| Carboplatin | 461 (21.00%) | 321 (69.63%) | 70 (15.18%) | 70 (15.18%) |
| Cisplatin | 447 (20.36%) | 338 (75.61%) | 66 (14.76%) | 43 (9.61%) |
| Immune therapy | 175 (7.97%) | 131 (74.85%) | 29 (16.57%) | 15 (8.57%) |
| Microtubule damaging | 133 (6.05%) | 114 (85.71%) | 15 (11.27%) | 4 (3.00%) |
| No chemotherapy | 436 (19.86%) | 344 (78.90%) | 82 (18.81%) | 10 (2.29%) |
| Other cytotoxic therapy | 24 (1.09%) | 22 (91.66%) | 2 (8.33%) | 0 (0.00%) |
| Oxaliplatin | 273 (12.43%) | 208 (76.19%) | 43 (15.75%) | 22 (8.05%) |
| Radiopharmaceutical | 39 (1.77%) | 24 (61.53%) | 8 (20.51%) | 7 (17.94%) |
| Targeted therapy | 558 (25.42%) | 443 (79.39%) | 77 (13.79%) | 38 (6.81%) |
| Taxane | 764 (34.80%) | 575 (75.26%) | 111 (14.52%) | 78 (10.20%) |
| Topoisomerase I inhibitor | 186 (8.47%) | 140 (75.26%) | 23 (12.36%) | 23 (12.36%) |
| Topoisomerase II inhibitor | 542 (24.69%) | 418 (77.12%) | 80 (14.76%) | 44 (08.11%) |
3D, 3-dimensional; IMRT, intensity modulated radiation therapy; VMAT, volumetric modulated arc therapy.